COAGRIV

Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. It doesn’t not involve antithrombin III (ATIII) to exert its anticoagulant effects and is an oral agent. No test is recommended for the assessment of the pharmacodynamics effects of rivaroxaban.

Absorption: Following oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hrs. Bioavailability is >80%. Distribution: Plasma protein binding is about 92%-95%. Metabolism: Approximately two-third of the dose is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independent mechanism. Elimination: Two-third of the rivaroxaban is excreted into urine and remaining one third via faeces.

Reduction in risk of stroke in non--valvular atrial fibrillation: For patient with CrCl>50mL/min, 20 mg once daily and CrCl 15-50mL/min is 15mg once daily. Treatment of DVT: 15mg BD with food for first 21 days, after 21 days transition to 20mg once daily with food for remaining treatment. For reduction of risk of recurrence of DVT and of PE 20 mg once daily with food. Prohylaxix of DVT following Hip or knee replacement surgery: In case of hip replacement surgery and for knee replacement surgery 10 mg of rivaroxaban is used for 35 and 12 days respectively for 6-10 hours after surgery once hemostasis has been established. 10mg of rivaroxaban can be taken irrespective of the food administration but 15 and 20 mg should be taken with the food.

Alu Alu strip of 10*10s